

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number
WO 02/38169 A1

(51) International Patent Classification⁷: **A61K 38/17,**
C07K 14/47, A61P 9/10, 17/06, 35/00

(21) International Application Number: **PCT/IT01/00563**

(22) International Filing Date:
8 November 2001 (08.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
RM2000A000578
8 November 2000 (08.11.2000) IT

(71) Applicant (for all designated States except US):
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Rome (IT).


(72) Inventors; and
(75) Inventors/Applicants (for US only): **MANTOVANI,**

Alberto [IT/IT]; c/o Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea, 62, I-20157 Milan (IT). **BOTTAZZI, Barbara** [IT/IT]; c/o Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea, 62, I-20157 Milan (IT). **PRESTA, Marco** [IT/IT]; c/o Dipartimento di Scienze Biomediche e Biotecnologiche, Facoltà di Medicina-Università' di Brescia, Via Valsabbina, 19, I-25123 Brescia (IT). **RUSNATI, Marco** [IT/IT]; c/o Dipartimento di Scienze Biomediche e Biotecnologiche, Facoltà di Medicina-Università' di Brescia, Via Valsabbina, 19, I-25123 Brescia (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: USE OF THE LONG PENTRAXIN PTX3 FOR THE TREATMENT OF DISEASES CAUSED BY AN ALTERED ACTIVATION OF THE GROWTH FACTOR FGF-2



WO 02/38169 A1

(57) Abstract: The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US*

- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

USE OF THE LONG PENTRAXIN PTX3 FOR THE TREATMENT OF DISEASES CAUSED BY AN ALTERED ACTIVATION OF THE GROWTH FACTOR FGF-2

The present invention relates to the use of the long pentraxin
5. PTX3 (PTX3) or one of its functional derivatives for the preparation of a medicament which inhibits the biological activity of the growth factor FGF-2, said medicament being useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.

10 Among the diseases brought about by an altered activation of the growth factor FGF-2 are included diseases provoked by an altered angiogenesis and by an uncontrolled proliferation of fibroblasts or smooth muscle cells.

15 The first compound endowed with antiangiogenic activity was discovered in the cartilage by Henry Brem and Judath Folkman in 1975 (J. Exp. Med. 1975 Feb. 1;141(2):427-39). The authors thought that this discovery could be used to control pathological process, such as tumor growth, metastasis, chronic and acute inflammation of the joint and diabetic retinopathy, using selective inhibitors of the 20 pathological neoangiogenesis.

Angiogenesis in the adult is normally quiescent, but it represents a normal function, for example in the healing of wounds, or in the reconstruction of the endometrium during the female reproductive cycle.

The angiogenic response is physiologically stimulated when the vascular functions are reduced and tissue perfusion is inadequate.

More generally, it can be claimed that, in physiological conditions, angiogenesis constitutes a positive feedback in response to inadequate perfusion, or to a reduced supply of oxygen and nutrients, such as occurs, for instance, in the case of occlusion of an artery, in situations of tissue mass growth (for example, the neovascularisation that accompanies the formation of muscle tissue); and in the case of an increased work load in association with an increased oxygen and nutrient requirement.

It is well known that the growth of a primary tumor is favoured by good vascularisation of the tumor tissue. An adequate supply of oxygen and nutrients promotes rapid growth of the tumor itself.

It has been demonstrated that the extent of angiogenesis can be an extremely negative factor in the prognosis of neoplasms (van Hinsbergh VW, Collen A, Koolwijk P; Ann. Oncol., 10 Suppl., 4:60-3, 1999; Buolamwini JK; Curr., Opin., Chem., Biol., 3(4):500-9, 1999 Aug.).

It is also known, in the tumor field, that a fundamental stage in the biology of the tumor cell is the acquisition of metastasising capability.

The tumor cells that metastasise are able to lose adherence to the surrounding structures, invade blood and lymphatic vessels and

colonise other tissues at a distance where they can continue to reproduce themselves.

Metastasising is also a critical event in the clinical history of the disease, being the main cause of death due to cancer. It is closely associated with and facilitated by the presence of vascular tissue in the tumor site or adjacent areas.

The migration of tumor cells across the surrounding structures enables the cells to reach the intra-tumor blood vessels, whether pre-existing or formed by neo-angiogenesis, and thus reach the bloodstream (Ray JM., Stetler-Stevenson WG; Eur. Respir. J., 7(11):2062-72, 1994; Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr; FASEB J., 7(15):1434-41, 1993 Dec.).

The presence of communication between lymphatic and blood vessels in the vascular region of the tumor enables the neoplastic cells to move in both vascular systems.

Recent studies have shown a direct relationship between angiogenesis and arthritic disease (Koch AE; Arthritis and Rheumatism 41:951-962, 1998). In particular, it has been demonstrated that neo-vascularisation of the articular cartilages plays a crucial role in pannus formation and in progression of arthritis. A normal cartilage does not possess blood vessels, while the synovial fluid of arthritic patients contains an angiogenesis-stimulating factor produced by endothelial cells (EASF).

The presence of this factor is associated with vascularisation and degradation of the cartilage.

Other diseases are also related to abnormal angiogenesis.

It has been found that, in diabetic retinopathy [Histol Histopathol. 1999 Oct; 14(4):1287-94], psoriasis [Br J Dermatol. 1999 Dec; 141(6):1054-60], chronic inflammation and 5 arteriosclerosis [Planta Med. 1998 Dec; 64(8):686-95], neovascularisation of the affected tissues is a facilitating factor.

The growth factor FGF-2 is a cationic polypeptides of 18kDa capable both of inducing neoangiogenesis *in vivo* and cells proliferation, chemotaxis and production of proteases in endothelial 10 cells in culture (Basilico and Moscatelli, 1992, Adv. Cancer Res. 59:115-65).

The role of FGF-2 in the tumoral angiogenesis is already known (Pathol. Biol. (Paris) 1999 Apr; 47(4):364-7).

In J. Pathol. 1999 Sept; 189(1):72-8 is reported that an 15 increased expression of FGF-2, in patients suffering from mesothelioma, is related to an higher aggressiveness and higher mortality of patients affected by such tumoral disease.

In Oncogene 1999 Nov 18;18(48):6719-24 is reported that 20 FGF-2 confers metastasising propriety to rat bladder carcinoma cells.

Int. J. Cancer 1999 May 5;81(3):451-8 reports that FGF-2 has a strong mitogenic activity, and is involved in the development of human tumors and in the increases of their malignity.

For the cure of tumoral diseases the antiangiogenic therapy respect to the standard traditional chemotherapy presents the following advantages (Cancer Research 1998, 58, 1408-16):

1. Higher specificity: it has as target the tumor neovascularisation process;
2. Higher biodisponibility: it has as target the endothelial cells, easy reachable without the problems linked to the traditional chemotherapeutic approach which act directly on the tumoral cells;
3. Minor chemoresistence: this may be the most important advantage of this therapy; in fact, being the endothelial cells, respect to the tumoral cells, genetically stable, phenomenon of drug resistance are improbable;
4. Minor metastasising: the blockage of the neovascularisation limits the propagation of the tumor cells in the other parts of the body through the bloodstream;
5. The apoptosis is favoured: the blockage of the vascular net in the tumor decrease the oxygen and nutrient availability for the tumoral cells, in this way the apoptosis is increased;
6. Reduction of the systemic toxicity: toxic effect, such as mielosuppression, gastrointestinal effects and transient alopecia, present with the traditional chemotherapy, are not observed with the antiangiogenic therapy.

To determinate these effects FGF-2 reacts with two different receptor classes present on target cells surfaces: the receptors

having high affinity endowed with tirosin kinases activity (FGFRs) and receptors endowed with low affinity represented by proteoglycan heparan sulfate (HSOGs) (Johnson and Williams, 1993, Adv. Cancer Res. 60:1-41; Moscatelli, 1987, J. Cell. Physiol. 131:123-30).

5 FGF-2 is a potent mitogen for medial smooth muscle cells and is necessary for their proliferation after balloon catheter injury (J. Biol. Chem. 2000 Apr. 14; 275 (15): 11270-7).

Therefore, diseases caused by an altered activation of the growth factor FGF-2 also include the hyperplasia of the muscular wall of the arteries that occurs during restenosis after angioplastic or "coronary stenting" [J. Vasc. Surg. 1997 Feb; 25(2):320-5].

10 The control of FGF-2 dependent neovascularisation represents one of the fundamental elements for the control and cure of diseases linked to an altered angiogenesis, as well as the control 15 of FGF-2-dependent uncontrolled proliferation of fibroblasts or SMCs is crucial for the treatment of cicatrization linked to excessive fibroblastic response and restenosis after angioplastic.

The availability of new therapeutical compound which specifically inhibit the biological activity of FGF-2 is an objective of 20 primary importance for the prevention and treatment of diseases brought about by an altered activation of this growth factor. Such diseases include arthritic disease, tumor, tumor metastasis, diabetic retinopathy, psoriasis, chronic inflammation, arteriosclerosis, cicatrization linked to excessive fibroblastic response and restenosis 25 after angioplastic.

PTX3 is expressed in various cell types (Bottazzi et Al., J., Biol. Chem. 1997, 272: 32817-32823) particularly in mononuclear phagocytes and endothelial cells, after exposure to the inflammatory cytokines Interleukin 1 β (IL-1 β) and Tumor Necrosis Factor alpha (TNF- α).
5

To date, the biological function of PTX3 has not yet been fully understood.

PTX3 consists of two structural domains, a N-terminal domain unrelated to any known molecule, and a C-terminal domain similar to the short pentraxins such as C-reactive protein (CRP)
10 (Breviario F., et al., J. Biol. Chem. 267:22190, 1992).

A substantial degree of similarity has been found between human PTX3 (hPTX3) and animal PTX3s. In particular, mouse PTX3 (mPTX3) is very similar to hPTX3 in terms of DNA sequence and
15 gene organisation and location. The degree of identity between human and murine PTX3 gene is 82%, and reaches 90% if conservative substitutions are considered (Introna M., et al.: Blood 87 (1996) 1862-1872). The murine PTX3 gene is located on chromosome 3 of the mouse in a region similar to the human 3q region (q24-28), in agreement with the documented location of hPTX3 in the 3q 25 region (Introna M., et al.: Blood 87 (1996) 1862-1872).
20

The high degree of similarity between hPTX3 and mPTX3 sequences is a sign of the high degree of conservation of pentraxins

during evolution (Pepys M.B., Baltz M.L.: Adv. Immunol. 34:141, 1983).

For a review about pentraxins see H. Gewurz et al, Current Opinion in Immunology, 1995, 7:54-64.

- 5 The international application WO99/32516, filed in the name of the applicant, describes the use of the long pentraxin PTX3 for the treatment of infective diseases, inflammatory or tumoral. The anti-tumor activity shown by PTX3, described in WO99/32516, is mediated by the leucocitary recruitment, i.e. on immunologic bases.
- 10 In WO99/32516 it is never described or suggested the use of PTX3 as useful agent for the treatment of diseases associated with an altered activation of the growth factor FGF-2.

US 5767252 describes a neuronal growth factor belonging to the pentraxin family (see also the references there cited). This patent 15 refers to the neurobiology sector.

It has now been found that the long pentraxin PTX3 is capable to bind the FGF-2 with high affinity and specificity. The binding of PTX3 with FGF-2 ($K_d = 8-16 \text{ nM}$) prevents the binding of the latter to its high affinity tyrosine-kinase receptors, and the 20 binding at the site of low affinity receptors, represented by the heparan-sulphate proteoglycans, present on the cell surface. The inhibition of the binding causes an inhibition of the FGF-2 biological activity.

The interaction between FGF-2/PTX3 depends on a correct 25 conformational structure of the growth factor, not only on its basic

nature, since PTX3 does not bind the cytocrome C (a protein that share with the FGF-2 molecular weight (18 kDa) and isoelectric point (pH 9,6)).

Moreover, the C-reactive protein, homologous to PTX3, does
5 not bind FGF-2.

Is therefore object of the present invention the use of the long pentraxin PTX3 or a derivatives thereof, or its domain, for preparing a medicament for the prevention and cure of diseases which are counteracted by the inhibition of the biological activity of the growth
10 factor FGF-2.

A further object of the present invention is the use of the long pentraxin PTX3 or a derivatives of the PTX3 or its domain, for preparing a medicament for the prevention and cure of diseases brought about by an altered activation of the growth factor FGF-2.

15 A further object of the present invention is the use of the long pentraxin PTX3 or a derivative thereof, or its domain, for preparing a medicament for the prevention or cure of diseases brought about by an altered angiogenesis, in which the altered angiogenesis is provoked by an altered activation of the growth factor FGF-2,
20 example of said diseases are: arthritic disease, tumor metastasis, diabetic retinopathy, psoriasis, chronic inflammation, arteriosclerosis or tumor, in which the tumor is, for example, sarcoma, carcinoma, carcinoid, bone tumor or neuroendocrine tumor.

A further object of the present invention is the use of the long pentraxin PTX3 or a derivatives of the PTX3 or its domain, for preparing a medicament for the treatment of diseases associated with uncontrolled FGF-2-dependent proliferation of fibroblasts or 5 smooth muscular cells, such as the cicatrization linked to excessive fibroblastic response, and the restenosis after angioplastie.

The compound according to the invention is suitable to be used for the inhibition of FGF-2 activity in target cells not only when it is administered as recombinant protein, but also when it is 10 administered endogenously in consequence of the gene transfer of its cDNA.

Is therefore a further object of the present invention the use of cDNA full length of human PTX3 or its derivative or its domain, for preparing plasmidic or viral expression vectors comprising said 15 cDNA, for the gene therapy of diseases caused by an altered activation of the growth factor FGF-2, in which the diseases are, for example, tumor, tumor metastasis, cicatrization linked to excessive fibroblastic response or restenosis after angioplastie.

For "long pentraxin PTX3" is intended any long pentraxin 20 PTX3, independently from its origin natural (human or animal) or synthetic.

For derivatives is intended any functional analogous of the long pentraxin PTX3 as above defined that bear at least a mutation, maintaining its functional capacity to selectively inhibit the FGF-2.

The preferred long pentraxin PTX3 is the human PTX3, which sequence is described in WO99/32516.

The long pentraxin PTX3 described herein can also be used in combination with one or more anticancer drugs for the treatment of tumor diseases in which the increased expression of FGF-2 provokes an higher aggressiveness of the tumor disease, or an higher metastasising capability.

In fact, it is well known that, to avoid the unwanted side effects maintaining the same therapeutic efficacy, most oncological patients are treated not with a single anticancer drug, but with a combination of several anticancer agents or with a combination of anticancer agents in association with antiangiogenic compounds.

The mechanism of action of the more usual anticancer drugs is completely different from the mechanism of action of the compound according to the present invention, in fact, the usual anticancer drugs are cytotoxic *vs* tumoral cells.

The compound according to the present invention having a different mechanism of action, exert a curative effect (adjuvant effect) additional to the effect exerted by the anti-tumor drug to which it is associated.

It is therefore a further object of the invention described herein the combination of the long pentraxin PTX3 with one or more known anticancer drugs.

A further object of the invention described herein is a pharmaceutical composition containing the long pentraxin PTX3 in

combination with one or more known anticancer drugs, such as alkylating agents, topoisomerase inhibitors, antitubulin agents, intercalating compounds, anti-metabolites, natural products such as vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxans, 5 and cyto-differentiating compounds, and one or more excipients or vehicles pharmacologically acceptable.

A further object of the invention described herein is the use of the long pentraxin PTX3, in combination with one or more known anti-tumor compounds, for preparing a medicament for the 10 treatment of tumor, in which the increased expression of FGF-2 provokes an higher aggressiveness of the tumor.

A further object of the invention described herein is the use of the long pentraxin PTX3, in combination with one or more known anti-tumor compounds, for preparing a medicament for the 15 prevention of the onset of tumor metastasis, in which the increased expression of FGF-2 provokes an higher metastasising capability.

A further object of the invention described herein is the use of the long pentraxin PTX3 in combination with the anticancer compound, for preparing a medicament for the treatment of tumor, 20 characterised in that the long pentraxin PTX3 is present as adjuvant of the anticancer compound.

The following examples illustrate the invention.

EXAMPLE 1**Capacity of PTX3 to bind FGF in solution.**

This experiment has been performed in order to evaluate PTX3 binding to FGF-2. PTX3 has been produced as described by Bottazzi et al., 1997, J. Biol. Chem. 272:32817-32823. Human recombinant FGF-2 has been produced as described by Isacchi A. et al., Proc. Natl. Acad. Sci. U.S.A. (1991), 88:2628-32. When necessary, FGF-2 has been labelled with ^{125}I following the method described by Isacchi et al. (see below).

10 Experimental procedure:

100 μl of PBS containing 1 μg of FGF-2 (or alternatively 1 μg of PTX3) were chromatographed on a size exclusion fast protein liquid chromatography Superose 12 column (Pharmacia): this column is able to separate proteins depending on their molecular weight. The column was eluted with PBS at a flow rate equal to 1 ml/minute and 1 ml fractions were collected and analyzed by dot blot with specific antibodies for the two proteins. In order to evaluate PTX3 binding to FGF-2 the two proteins (5 μg and 1 μg , respectively) were mixed in 100 μl PBS and incubated at 4°C for 10 min. before loading onto the column. Fractions were collected and analysed by dot-blot with anti FGF-2 specific antibodies. The results reported in figure 1 show that FGF-2 (18.000 D) is eluted from the column with a retention volume of approximately 22 ml. In the same conditions PTX3 (450.000 D) is eluted with the void volume of the column (7 ml.) When FGF-2 pre-incubated with PTX3 for 10 min. at 4°C was

loaded onto the column, a change in its chromatographic behaviour was observed: in this experimental conditions FGF-2 was eluted from the column with a retention volume equal to PTX3 alone.

EXAMPLE 2

5 **Capacity of biotinylated PTX3 to bind plastic immobilised FGF-2**

100 µl of NaHCO₃ pH 9.6 containing 500 ng of FGF-2 or of the complement component C1q were incubated 18h at 4°C in 96 wells plastic plates. At the end of incubation wells were washed 3 times with PBS and subsequently incubated 2h at room temperature with 10 200 µl of PBS containing 1 mg/ml of Bovine Serum Albumin (BSA). At the end of incubation wells were washed again 3 times with PBS and incubated with 30 ng/ml of ¹²⁵I-FGF-2 in presence of increasing amounts of biotinylated PTX3 in 100 µl of PBS (2h at room temperature). Alternatively wells were adsorbed with increasing 15 doses of FGF-2 or C1q and incubated with 100 ng/ml of biotinylated PTX3 in 100 µl of PBS. After this incubation wells were washed 3 times with PBS and incubated 1h at room temperature with 100 µl of streptavidin HRP conjugate (1/2000). Reaction was developed by adding the chromogen microwell peroxidase substrate system ABTS (Kirkegaard & Perry Laboratories). Plates were read in an automatic 20 ELISA reader at 405 nm. Results reported in figure 2 demonstrate that FGF-2 immobilised on plastic wells is able to bind biotinylated PTX3 in a way similar to the physiologic PTX3 ligand C1q (Bottazzi B. et al., 1997, J. Biol. Chem. 272:32817-32823).

EXAMPLE 3**Characterisation of PTX3-FGF-2 interactions**

96 wells plates were coated at 4°C with 100 µl of NaHCO₃ pH 9.6 containing PTX3 or C reactive protein (200 nM) or alternatively 5 µg /ml of the following proteins used as negative control: bovine serum albumin, fibronectin, gelatine or laminin. After incubation, wells were washed 3 times with PBS and blocked 2h at room temperature with 200 µl of 1 mg/ml of BSA in PBS. At the end of incubation wells were washed 3 times with PBS and subsequently 10 incubated with 30 ng of ¹²⁵I-FGF-2 for 2 h at room temperature. Wells were subsequently washed 3 times with PBS and bound ¹²⁵I-FGF-2 was recovered by washing each well twice with 200 µl of 2% SDS in water. Levels of ¹²⁵I-FGF-2 were measured in a gamma counter. Results reported in figure 3 shows that FGF-2 binds plastic 15 immobilised PTX3 and that this binding is specific since FGF-2 reacts poorly with CRP and does not react with other immobilised proteins.

EXAMPLE 4**¹²⁵I-FGF-2 binding to plastic immobilised PTX3 in the presence 20 of an excess of cold FGF-2**

In a second set of experiments the binding of ¹²⁵I-FGF-2 to plastic immobilised PTX3 has been tested in the presence of an excess of both native or heat denatured cold FGF-2 (100 nM), in the presence of similar Cytochrome C concentrations or in the presence of 25 an excess of soluble PTX3 (300 nM). The experiment was performed

as described above; The results reported in figure 4 demonstrate that cold FGF-2 and soluble PTX3 inhibited the interaction between ¹²⁵I-FGF-2 and plastic immobilised PTX3. The observation that heat-inactivated FGF-2 and Cytocrome C (having the same molecular weight and isoelectric point as FGF-2) are not able to bind PTX3 suggests that a correct conformation of the growth factor rather than its basic nature is involved in its capacity to bind PTX3.

EXAMPLE 5

Dissociation constant (Kd) of FGF-2/PTX3 interaction

With this experiment the dissociation constant (Kd) of FGF-2/PTX3 interaction has been determined. For this purpose increasing doses of ¹²⁵I-FGF-2 were incubated with plastic immobilised PTX3 and binding results were analysed by Scatchard plot. Results reported in figure 5 demonstrate that FGF-2 binds PTX3 in a saturable way and with elevated affinity (Kd = 8-16 nM). This affinity is similar to the affinity previously calculated for the interaction of PTX3 with its physiological ligand C1q.

EXAMPLE 6

Effect of PTX3 on FGF-2 binding to Endothelial Cells

Transformed foetal bovine aortic endothelial cells GM7373 were seeded at 80,000 cells/cm² in 24-well dishes in Eagle's minimal essential medium (Eagle's MEM) containing 10% FCS. After 24 h at 37°C adherent cells were washed twice with Eagle's MEM without FCS and subsequently incubated for 2 h at 4°C with ¹²⁵I-FGF-2 (10 ng/ml) in Eagle's MEM containing 0.15% gelatine and 20

mM HEPES pH 7.5 in the absence or in the presence of increasing concentrations of PTX3. At the end of incubation the amount of ¹²⁵I-FGF-2 bound to low (HSPGs) and high affinity receptors (FGFR) was evaluated as described by Moscatelli, 1987 J. Cell. Physiol. 131:123-

5 30. Briefly cells were rinsed twice with 2 M NaCl in 20 mM HEPES buffer (pH 7.5) to remove ¹²⁵I-FGF-2 bound to low-affinity binding sites and twice with 2 M NaCl in 20 mM sodium acetate (pH 4.0) to remove ¹²⁵I-FGF-2 bound to high-affinity binding sites. Non-specific binding was measured in the presence of a 100-fold molar excess of
10 unlabeled FGF-2 and subtracted from all the values. Results reported in figure 6 shown that PTX3 is able to inhibit in a dose-dependent manner the binding of FGF-2 to its high- and low-affinity receptors on endothelial cells.

EXAMPLE 7

15 **Effect of PTX3 on mitogenic activity exerted by FGF-2 on endothelial cells**

GM 7373 cells were seeded at 75,000 cells/cm² in 48-well plates in Eagle MEM containing 10% FCS. After 24 h at 37°C adherent cells were washed twice with Eagle's MEM without FCS
20 and subsequently incubated for 24 h at 37°C in Eagle's MEM containing 0.4 % FCS in the absence or in the presence of FGF-2 (10 ng/ml) and increasing concentrations of PTX3. At the end of incubation cells were trypsinized and counted. In a different set of experiments GM 7373 cells were treated as described above in the
25 presence of different mitogenic stimuli: 10% FCS; 5 µg/ml dyacyl-

glycerol (DAG); 10 ng/ml phorbol ester (TPA) 30 ng/ml epidermal growth factor (EGF) or 30 ng/ml vascular endothelial growth factor (VEGF). Results reported in figure 7 shown that PTX3 inhibits the mitogenic activity exerted on endothelial cells by FGF-2 in a dose-dependent manner with an ID₅₀ equal to 30 nM. This value is similar to the Kd calculated for the interaction FGF-2-PTX3. These results suggest that the inhibition of FGF-2 biological activity by PTX3 is due to its sequestration in extracellular sites. The inhibitory activity of PTX3 on FGF-2 is specific since it is not detectable when other mitogens are used to induce cellular proliferation.

EXAMPLE 8

Effect of PTX3 on the proliferation of transformed foetal bovine aortic endothelial cells

In this experiment we have investigated the effect of PTX3 on the proliferation of the murine aortic endothelial cell line MAE3F2T stably transfected with an expression vector coding for FGF-2 (Gualandris et al. 1996, Cell Growth Diff. 7:147-60). These cells can proliferate in response to a autocrine loop of stimulation induced by endogenous FGF-2 (Gualandris et al. 1996, Cell Growth Diff. 7:147-60). MAE3F2T cells were seeded at 10,000 / cm² in 48-well plates in Dulbecco medium (DMEM) added with 10% FCS. After 24 h at 37°C, adherent cells were washed twice with DMEM without FCS and incubated for 72 at 37 °C in DMEM containing 0.4 % FCS in the presence or not of PTX3 (70 nM), anti FGF-2 specific antibodies or suramin (50 µg/ml). Suramin is known for its capacity to

sequestrate extracellular FGF-2 and inhibits its biological activities (Rusnati et al., 1996, Mol. Biol. Cell. 7:369-381). At the end of incubation cells were trypsinized and counted in a Burker chamber. Results reported in figure 8 shown that PTX3 is able to block the 5 autocrine loop of stimulation induced by FGF-2 in MAE3F2T cells, inhibiting their FGF-2 dependent proliferation, in a manner similar to that exerted by anti FGF-2 antibodies and suramin.

EXAMPLE 9

Effect of PTX3 onto the neovascularization induced in vivo by FGF-2

The antiangiogenic potential of PTX3 was evaluated in vivo in the chick embryo chorioallantoic membrane (CAM) assay. Briefly, a window was opened in the egg shell of 3 day-old fertilized chicken eggs. At day 8, gelatin sponges were implanted on the CAMs and 15 adsorbed with 10 ul of PBS alone or containing FGF-2 (at 500 ng/sponge) in the absence or in the presence of PTX3 (5 ug/sponge) (5-6 embryos per group). After 4 days, CAMs were observed *in ovo* under a Zeiss SR stereomicroscope and the angiogenic response was scored by two investigators without knowledge of the samples tested 20 and graded on an arbitrary scale of 0-4+, with 0 representing no angiogenic response and 4+ representing the strongest activity.

Results reported in figure 9 shown that PTX3 is able to block the neovascularization induced in vivo by FGF-2.

EXAMPLE 10**Gene therapy with PTX3**

Murine endothelial cells overexpressing FGF-2, named FGF2MAE3F2T (Gualandris et al. 1996, Cell Growth Diff. 7:147-60) 5 were transfected with human PTX3 full length cDNA subcloned in the commercial expression vector pLXSH (Clontech).

In vitro studies on the transfected cell lines obtained were performed to study the effect of PTX3 over-expression on FGF-2-dependent proliferation of FGF2MAE3F2T cells and their invasive behaviour on three-dimensional fibrin gels. 10

In details, several FGF2MAE3F2T clones expressing different levels of PTX3 and parental FGF2MAE3F2T cells (that do not produce PTX3) were seeded at 10,000/ cm² in 48-well plates in Dulbecco medium (DMEM) added with 10% FCS. After 24 h at 37°C, 15 adherent cells were washed twice with DMEM without FCS and incubated for different period of time at 37 °C in DMEM containing 0.4 % FCS. At the end of incubations cells were trypsinized and counted in a Burker chamber. Results reported in figure 10 shown that PTX3 over-expression inhibits FGF2MAE3F2T cells proliferation and that the extent of this inhibition correlates with the amount of 20 PTX3 produced by the different clones tested.

To evaluate the invasive behaviour of FGF2MAE3F2T clones over-expressing PTX3 on three-dimensional fibrin gels, cell aggregates were prepared on agarose-coated plates exactly as 25 described (Gualandris et al. 1996, Cell Growth Diff. 7:147-60). These

aggregates were seeded onto fibrin-coated 48 well-plates. Immediately after seeding, 250 l of calcium-free medium containing fibrinogen (2.5 mg/ml) and thrombin (250 mU/ml) were added to each well and allowed to gel for 5 min at 37°C. Then, 500 l of culture medium were added on the top of the gel. In all the experiments, the fibrinolytic inhibitor trasyloL was added to the gel and to the culture medium at 200 KIU/ml to prevent the dissolution of the substrate. Formation of radially growing cell sprouts was evaluated after 2 days by computerized image analysis.

Results reported in figure 11 shown that the invasive capacity of PTX3 over-expressing FGF2MAE3F2T clones is significantly lower than that of parental FGF2MAE3F2T cells.

The results obtained demonstrate that PTX3 inhibits FGF-2 activity in endothelial cells when it is endogenously produced after gene transfer of its cDNA.

Thus, the compound according to the invention can be used in gene therapy protocols in accordance to known methods (In Vivo. 1998 Jan-Feb; 12(1):59-67; In Vivo. 1998 Jan-Feb; 12(1):35-41; In Vivo. 1994 Nov-Dec; 8(5):771-80) for the treatment of diseases caused by an altered activation of the growth factor FGF-2.

CLAIMS


1. Use of the long pentraxin PTX3 or a derivative thereof or its domain, for preparing a medicament for the prevention and cure of diseases which are counteracted by the inhibition of the biological activity of the growth factor FGF-2.
2. Use according to claim 1, in which said diseases are brought about by an altered activation of the growth factor FGF-2.
3. Use according to claim 2, in which said altered activation of the growth factor FGF-2 provokes a disease linked to an uncontrolled proliferation of fibroblasts or smooth muscle cells.
4. Use according to claim 3, in which the disease is selected from the group consisting of cicatrization linked to excessive fibroblastic response and restenosis after angioplasty.
5. Use according to claim 2, in which said altered activation of the growth factor FGF-2 provokes an altered angiogenesis.
6. Use according to claim 5, in which the disease provoked by an altered angiogenesis is selected from the group consisting of arthritic disease, tumor, tumor metastasis, diabetic retinopathy, psoriasis, chronic inflammation and atherosclerosis.
7. Use according to claim 6, in which the tumor is selected from the group consisting of sarcoma, carcinoma, carcinoid, bone tumor and neuroendocrine tumor.
8. Use according to any of the preceding claims, in which the long pentraxin PTX3 is the PTX3 present in nature.

9. Use according to claim 8, in which the long pentraxin PTX3 is the human PTX3.
10. Use according to claim 1-7, in which the long pentraxin PTX3 is the PTX3 from synthetic origin.
- 5 11. Use of the cDNA that code for the long pentraxin PTX3 or its derivative or its domain, for preparing expression vectors comprising said cDNA, for the gene therapy of diseases caused by an altered activation of the growth factor FGF-2.
- 10 12. Use according to claim 11, in which said cDNA containing the gene coding for PTX3 or its derivative is carried by a plasmidic or viral vector.
- 15 13. Use according to claim 11, in which the disease is selected from the group consisting of tumor, tumor metastases, cicatrization linked to excessive fibroblastic response and restenosis after angioplasty.
14. Combination of the long pentraxin PTX3 with one or more known anticancer drugs.
15. Pharmaceutical composition containing as active ingredient the combination of claim 14, and one or more excipients or vehicles 20 pharmacologically acceptable.
16. Composition of claim 15, in which the anticancer drug is selected from the group consisting of alkylating agents, topoisomerase inhibitors, antitubulin agents, intercalating compounds, anti-metabolites, natural products such as vinca


alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxans, and cyto-differentiating compounds.

17. Use of the long pentraxin PTX3 with one or more known anticancer drugs for preparing a medicament for the treatment of tumor, in which the increased expression of FGF-2 provokes an higher aggressiveness of the tumor.
5. 18. Use of the long pentraxin PTX3 with one or more known anticancer drugs for preparing a medicament for the prevention of the onset of tumor metastasis, in which the increased expression of FGF-2 provokes an higher metastasising capability.
10. 19. Use according to claim 17 or 18, characterised in that the long pentraxin PTX3 is present as adjuvant of the anticancer drug.


1/6

Figure 1


5

Figure 2

2/6


Figure 3

5

Figure 4

10


3/6

Figure 5

5



Figure 6

10




15


4/6

Figure 7


5

Figure 8


5/6

Figure 9

5

Figure 10

6/6

Figure 11

INTERNATIONAL SEARCH REPORT

Int	nal Application No
PCT/IT 01/00563	

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	A61K38/17	C07K14/47	A61P9/10	A61P17/06
A61P35/00				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 32516 A (SIGMA-TAU INDUSTRIE FARMACEUTISCHE RIUNITE S.P.A.) 1 July 1999 (1999-07-01) cited in the application claims 1-18	1-3,5-19
A	M. M. LUCHETTI ET AL: "Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA)" CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 119, January 2000 (2000-01), pages 196-202, XP002191383 abstract	1-19 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

26 February 2002

Date of mailing of the international search report

14/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IT 01/00563

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	N. POLENTARUTTI ET AL: "Interferon-gamma inhibits expression of the long pentraxin PTX3 in human monocytes" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, 1998, pages 496-501, XP002191384 abstract	1-19
A	B. BOTTAZZI ET AL: "Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 52, 26 December 1997 (1997-12-26), pages 32817-32823, XP002191385 cited in the application abstract	1-19
A	INTRONA M ET AL: "Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 5, 1 March 1996 (1996-03-01), pages 1862-1872, XP002113121 ISSN: 0006-4971 cited in the application the whole document	1-19

INTERNATIONAL SEARCH REPORT
Information on patent family members

Int'l Application No
PCT/IT 01/00563

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9932516	A 01-07-1999	IT	RM970796 A1	21-06-1999
		AU	1782999 A	12-07-1999
		EP	1034185 A2	13-09-2000
		WO	9932516 A2	01-07-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADING TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.